DOJ Offers Big Incentive to Healthcare Industry to Self-Disclose Criminal Conduct

Perkins Coie

Perkins Coie

The U.S. Department of Justice (DOJ) announced a “road map” for the healthcare industry last month to guide voluntary self-disclosures and cooperation with government investigations. Speaking at the annual American Health Lawyer’s Association (AHLA) Fraud & Compliance Forum in Baltimore, Sally Molloy, Assistant Chief, DOJ Criminal Division, Fraud Section, Health Care Fraud Unit, announced that her office will immediately begin using the guidelines outlined in DOJ’s Foreign Corrupt Practices Act (FCPA) Corporate Enforcement Policy to govern corporate self-disclosures of healthcare fraud and other potentially criminal conduct by healthcare entities. Molloy indicated the Health Care Fraud Unit wants to provide greater clarity and certainty to healthcare organizations about the benefits of self-disclosure and cooperation. Molloy’s announcement is consistent with other DOJ announcements earlier in the year about expanding the application of the policy beyond the FCPA.

Healthcare organizations that do not have international operations may be unfamiliar with the FCPA Corporate Enforcement Policy. It began as a 2016 pilot project designed to incentivize voluntary self-disclosures by corporations, and to promote transparency and accountability in government charging decisions. It was formalized and incorporated into the United States Attorneys’ Manual in late 2017. It provides that, absent aggravating circumstances, there is a presumption that a company will receive a declination from prosecution so long as the company:

            (1) voluntarily self-discloses the misconduct;

            (2) fully cooperates with DOJ; and

            (3) timely and appropriately remediates the problems.

In situations where aggravating circumstances exist and DOJ determines a criminal resolution is warranted, despite full compliance with the policy, DOJ may give a company partial credit. This consists of reductions from the low end of the United States Sentencing Guideline fine ranges and not requiring the appointment of a monitor. DOJ also may give limited credit in situations where a company has not voluntarily self-disclosed the misconduct, but later fully cooperated and timely and appropriately remediated in accordance with the policy.

This update summarizes the basic elements of the FCPA Corporate Enforcement Policy and its application to the healthcare industry. We also analyze some of the issues that healthcare companies should consider before making a self-disclosure in accordance with the policy.

Key Requirements of FCPA Corporate Enforcement Policy

While the FCPA Corporate Enforcement Policy was drafted with a specific statute in mind, its principles are generally applicable to the healthcare industry. Many of its requirements are consistent with—though in some ways more extensive than—existing self-disclosure protocols that are specific to the healthcare industry.

Voluntary Self-Disclosure

There are three factors DOJ uses to determine whether a self-disclosure was voluntary:

  1. The disclosure occurred “prior to an imminent threat of disclosure or government investigation.” DOJ wants to reward true self-disclosures. It will not provide the same rewards to companies who come forward only because they know they’re about to be caught.
  2. The conduct was disclosed “within a reasonably prompt time after becoming aware of the offense.” DOJ will not look favorably on disclosures that were delayed, perhaps for some strategic benefit to the disclosing company. For full credit, disclosures must occur contemporaneously with the identification and remediation of the misconduct and the burden is on the company to demonstrate timeliness.
  3. The company discloses “all relevant facts” known to it, including “all relevant facts about all individuals involved in the violation of law.” Healthcare companies and their counsel should be familiar with DOJ’s focus on individual misconduct from the 2015 Yates Memo. The inclusion of this requirement illustrates that DOJ continues to focus on individual misconduct, particularly in the criminal context.

Full Cooperation

DOJ expects disclosing entities to provide proactive and transparent cooperation. Strategic or partial disclosures of information are not sufficient. To receive full credit for its cooperation, a company must satisfy five requirements:

  1. Timely disclosure of all facts relevant to the conduct at issue. DOJ expects companies to disclose all relevant facts and attribute those facts to specific sources rather than just providing a general narrative (subject to attorney-client privilege constraints). In addition, the policy requires timely updates on the company’s internal investigation; information regarding the involvement of the company’s officers, employees or agents in criminal conduct; and information the company knows about the involvement of third parties in criminal conduct.
  2. Proactive, not reactive, disclosure of facts and information. DOJ expects the company to disclose relevant facts without having to be asked. If there are relevant sources of information that the company is aware of but doesn’t have access to, DOJ also expects the company to flag those sources.
  3. Timely preservation, collection and disclosure of relevant documents. DOJ expects detailed information about the company’s document collection and preservation efforts. It also expects companies to “facilitate” third-party production of documents. This element can be tricky to navigate, even for companies with contractual rights to obtain documents and information from third-party sources, such as downstream providers or vendors.   
  4. “De-confliction” of witness interviews and investigative steps. In criminal investigations, DOJ may wish to take certain steps before the company does, or delay certain steps, such as interviews of key witnesses. DOJ does this to protect the integrity of the investigation or to avoid conflicts with broader DOJ enforcement efforts. In such situations, DOJ may ask the company to delay portions of its internal review, which may hinder the company’s ability to satisfy all the required elements under the Enforcement Policy. DOJ recognizes this inherent conflict, and states any of its de-confliction requests will be narrowly tailored in scope and duration.
  5. Making relevant employees, agents and third-party witnesses available for interviews by DOJ, including former officers and employees. DOJ expects companies to make significant efforts to assist DOJ in interviewing witnesses, subject to individuals’ Fifth Amendment rights. This factor may be the one that many healthcare companies may be unfamiliar with, and perhaps least comfortable. Companies will need to carefully consider whether and how they will provide counsel for current and former employees.

Timely and Appropriate Remediation

Self-disclosing misconduct and cooperating is not enough. DOJ expects companies to provide detailed information demonstrating that the company understands why and how the misconduct happened and has taken decisive steps to ensure it won’t happen again. The factors DOJ will consider include:

  • A root cause analysis and appropriate remediation. The FCPA Corporate Enforcement Policy provides that a company must pay “all disgorgement, forfeiture, and/or restitution” resulting from the self-disclosed conduct. But the return of improperly obtained government funds (and payment of fines or penalties) is only the beginning. DOJ also expects companies to investigate the root cause of the circumstances leading to the misconduct. Additional remedial steps, such as implementation of enhanced internal controls, also may be appropriate. 
  • Implementation of an effective compliance and ethics organization. Healthcare companies have the benefit of decades of HHS OIG guidance on effective compliance programs, and, consequently, the bar to satisfying this element may be high. Sally Molloy told the AHLA audience that DOJ is not satisfied with a description of a company’s policies and procedures and basic statistics. DOJ wants disclosing companies to demonstrate how their compliance programs live and breathe, and for companies to provide evidence showing that the compliance program actually works. DOJ’s position is consistent with recent guidance from HHS OIG on how to measure compliance program effectiveness.
  • Appropriate discipline of employees. When appropriate, DOJ may expect companies to go beyond the obvious disciplinary measures. For example, companies may be encouraged to claw back compensation from executives who were responsible for the business units where misconduct occurred.
  • Appropriate retention of business records. DOJ’s policy notes that companies should prohibit the use of “software that generates but does not appropriately retain business records or communications.” While this will not be a major concern for traditional forms of records (e.g., medical records), healthcare companies should understand what messaging apps and other electronic communication platforms their employees are using and whether those systems are consistent with appropriate retention of business-related records and communications. 
  • Additional steps. Leaving itself some flexibility, DOJ’s policy includes a “catch all” category for any other actions that might be appropriate under the circumstances.

Aggravating Circumstances

Even when a company makes a voluntary self-disclosure, fully cooperates with DOJ and appropriately remediates misconduct, DOJ still may seek a criminal resolution where there are “aggravating circumstances.” These circumstances include misconduct by the company’s executive management, significant profit from company misconduct, pervasiveness of the misconduct within the company and criminal recidivism. However, even if one or more aggravating circumstances exist, companies should remember that they still may receive a 50% reduction from the low end of the United States Sentencing Guideline fine ranges and not be required to appoint an independent monitor.


DOJ’s decision to follow the FCPA Corporate Enforcement Policy in the healthcare industry provides companies with a potentially significant benefit for self-disclosing fraudulent conduct. However, companies still must deal with the thorny decisions surrounding any decision to self-disclose improper conduct to a regulator. Some of the issues that healthcare companies should consider before deciding to take advantage of this avenue for self-disclosure include:

  • Application. One of the first questions a company needs to answer when deciding to make a self-disclosure is “which government agency should receive it?” To make the most of a self-disclosure to DOJ’s Healthcare Fraud Unit, a company should be reasonably confident that DOJ would consider the disclosed conduct to be a violation of a criminal statute. But what if there is overlapping or parallel jurisdiction, as is frequently the case in healthcare? For example, HHS OIG has authority to resolve civil lability for potential violations of the Anti-Kickback Statute (AKS) and a well-developed self-disclosure program. Answering the “which agency” question will require a careful weighing of the pros and cons of each available option. Especially in the AKS context, companies need to be aware that a self-disclosure to DOJ does not toll the 60-day repayment requirement the way that a self-disclosure to OIG does.

    Further, Molloy’s announcement that her office intends to follow the FCPA Corporate Enforcement Policy for healthcare cases is a good indicator, but not a guarantee, that local U.S. Attorney’s Offices will follow suit.  
  • Timing. Healthcare companies that have enhanced their compliance programs and internal controls in response to CMS’ Final Rule for Reporting and Returning Overpayments[1] should be well-positioned to respond quickly to identified problems. However, we are in an era of aggressive whistleblowing and expansive theories of liability. If a company expects that investigation and remediation of an issue may take more than a few months, or that the risk of a whistleblower is particularly high, it should consult counsel regarding options for making preliminary or interim reports to enforcement authorities while the investigation and remediation work is ongoing. Crafting a comprehensive self-disclosure takes time, and companies do not want to be beat to the punch.
  • Potential Impact on Work Product Doctrine. As described above, DOJ expects self-disclosures to be comprehensive as to “all relevant” facts and information about the disclosed conduct, including information specific to involved individuals. DOJ is careful to state that none of the requirements of the FCPA Enforcement Policy require waiver of either the attorney-client privilege or work product doctrine. And, at the AHLA conference, Molloy was careful to state that the DOJ’s “Principles of Federal Prosecution of Business Organizations” (commonly referred to as the Filip Memo), which prohibit DOJ from forcing companies to waive the attorney-client privilege, still apply under the FCPA Corporate Enforcement Policy. However, recent case law demonstrates that there is a needle-threading exercise inherent in making a self-disclosure of “all relevant facts” and fully cooperating, and there is a risk that companies will find they have inadvertently waived their protections.[2]   
  • Recidivism. One of the aggravating factors that could prevent a company from otherwise receiving full credit for a self-disclosure is recidivism. Understandably, the DOJ does not want to give repeat offenders a free pass for repeated bad behavior, but it has not been completely clear on what it considers to be recidivist conduct. The FCPA policy refers to “criminal recidivism.” In the healthcare context, will DOJ take the position that prior civil fraud, such as False Claims Act settlements, constitute recidivist conduct? Healthcare companies that are actively engaged in mergers and acquisitions should be wary. DOJ has informally stated that it will give full credit to acquiring companies who identify misconduct during due diligence or post-closing audits, but has not formalized this policy or specifically applied it to the healthcare industry yet. Further, many healthcare companies are massive organizations with subsidiaries, affiliates and joint ventures. In a complex environment, problematic conduct can still occur even with the most robust compliance programs. Given the lack of clarity from DOJ, companies are left to wonder whether they will only have one bite at the apple for full disclosure credit.
  • Partial Credit. Even if a company cannot satisfy each element of the FCPA Corporate Enforcement Policy, making a self-disclosure in accordance with the policy’s requirements may still be worthwhile. In addition to the tangible benefits available under the policy (reductions in fines, no monitor), companies can build credibility and demonstrate their bona fides as good corporate citizens to the government through transparency and cooperation. Having that credibility can pay big dividends the next time the company finds itself in front of the government.

The question of whether to self-disclose will always be difficult and intensely dependent upon the facts and circumstances of the issue at hand. While DOJ’s announcement provides guideposts for healthcare organizations, companies should always engage experienced counsel to help navigate the uncertain road ahead.


[1] Reporting and Returning of Overpayments, 81 Fed. Reg. 7654 (Feb. 12, 2016)

[2] See e.g. SEC v. Herrera, No. 17-cv-20301, 2017 WL 6041750 at *5 (S.D. Fla. Dec. 5, 2017) (holding that work product protection for attorney interview notes and memoranda was waived when company lawyers provided “oral downloads” of the interviews to the Securities and Exchange Commission)

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Perkins Coie | Attorney Advertising

Written by:

Perkins Coie

Perkins Coie on:

Readers' Choice 2017
Reporters on Deadline

Related Case Law

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.